CEC Capital announced today the promotion of Mr. Li Jin, Managing Director and Medtech Division Head within the healthcare investment banking team, to Partner.

With over a decade of experience in the medical and healthcare industry and investment sector, Mr. Li Jin joined CEC Capital in 2020 and has been leading the Medtech team within the company's healthcare investment banking division.

Under his leadership, the Medtech Team at CEC Capital has successfully completed transactions exceeding a total value of RMB 10 billion over the past two years. Notable transactions include investments in Accunome Science by bioMérieux, WuXi Diagnostics, OrbusNeich, Sinovation, NuProbe, Visionmedicals, Reliable Med, Health Biotech, Changmugu Decans Medical, b-ONE, HuiHe Healthcare, AccuMedical, Sy Map medical, Ronovo, Wivest Medical, Fussen Tech, UnionStrong Tech, GenomePrecision Tech and Concare. This establishes CEC Capital's leading position in China's Medtech sector.

The advisory services provided to bioMérieux in its investment in Accunome Science showcase CEC Capital's strong industry knowledge and outstanding deal-making capabilities in serving multinational corporations and listed companies.

Among these, serving as the buyer's advisor for bioMérieux's investment in Accunome is an example of CEC Capital's deep engagement with MNCs and publicly-listed companies. This reflects CEC Capital’s deep industry understanding and exceptional deal-matching capabilities.

Mr. Li Jin holds a master's degree in Biochemistry and Molecular Biology from Sun Yat-sen University and an MBA degree from Peking University's Guanghua School of Management. Before joining CEC Capital, he held key positions at companies at GSK, Mindray, ASB Ventures, and BGI Co-win.

Additionally, CEC Capital announced the appointment Ms. Liao Jieying as Managing Director and Head of the Synthetic Biology Division within the Healthcare Investment Banking Team.

Ms. Liao Jieying brings extensive experience in the synthetic biology industry and investment sector, with a unique background in research, industry, and investment. She has previously engaged in infectious disease research at the National Institutes of Health in the United States and held various roles in BGI Genomics, FJIRSMCAS , CAS VENTURE CAPITAL, and Cash Capital.

Prior to joining CEC Capital, Ms. Liao Jieying served as an investment partner at Cash Capital, where she focused on private equity investments in the healthcare industry. Her representative projects included Mabworks Biotech, Thousand Oaks Biologics, INNOGEN, RNACure, TIAN JIAN, Biocreatech and CASMN.

Ms. Liao Jieying holds a bachelor's degree in Biochemistry from Lanzhou University and a Ph.D. in Biophysics from the Institute of Biophysics, Chinese Academy of Sciences.